Rayman Khan’s Post

With the introduction of the Cannabis Act 2024 (CanG 2024) in Germany on April 1, 2024, the landscape of the medical cannabis industry has undergone notable changes. While the act primarily legalises recreational cannabis, its implications extend deeply into the medical sector, affecting everything from patient access to industry dynamics. Read the full article by clicking the link below 👇 https://lnkd.in/eGH4ZVgU

The DEA will begin the regulatory process to reschedule cannabis (marijuana) from Schedule I to Schedule III under the Controlled Substances Act, thereby making it a less controlled drug. The implication for intellectual property is the prospect of opening federal trademark registration to marijuana manufacturers, distributors, growers, and retailers, who were otherwise prohibited from seeking protection of their cannabis-related trademarks and service marks. #trademark #cannabislaw #intellectualproperty #rescheduling #trademarklaw https://lnkd.in/gaJwyYvc

🌱 New Model for Cannabis Quality Standards: A Step Towards Equivalence Between Medicinal and Recreational Use 🌱 The implementation of this innovative model will finally establish equivalence in quality between medical cannabis and recreational cannabis, considering essential factors like cannabinoid content, the presence of heavy metals, pesticides, hormones, and other critical parameters. This shift will ensure greater control over production processes, which will now adopt pharmaceutical-like protocols and certifications, significantly improving the entire production chain. 🔍 Rigorous Quality Control Measures in Germany To maintain the highest product quality standards in cannabis dispensaries, the German government has introduced a rigorous system of periodic inspections, ensuring that all activities involved in cannabis distribution are regularly checked. This initiative guarantees consumers access to safe and high-quality products for both medicinal and recreational purposes. 💡 Ensuring Human Well-Being With approximately 23 million consumers in Europe and the numbers growing due to evolving regulations, it is essential that production processes adhere to the highest standards. As countries across the union continue to regulate cannabis, it's likely that this model will be replicated in other nations by 2026, ensuring the health and well-being of all citizens. This is a pivotal step for the future of the cannabis sector. 🌍 QUALITY IS THE KEY GQCan HESALIS - Planet Based Company #Cannabis #MedicalCannabis #RecreationalCannabis #QualityControl #CannabisRegulation #PharmaceuticalStandards #Sustainability

In Italy, the hemp industry is pushing back against government efforts to criminalize light cannabis, potentially jeopardizing thousands of jobs and a €500 million market. 🇮🇹 Meanwhile, Poland is looking at introducing stricter regulations on medical cannabis prescriptions, sparking debate over patient access. 🇵🇱 Over in Norway, there’s are new proposals to legalise cannabis. Though unlikely to pass amid strong opposition from across the political spectrum, it is helping drive a fresh conversation about cannabis liberalisation in the historically drug-reform-averse country. 🇳🇴 https://lnkd.in/ezCXugti

Hawaii's legislature is currently considering a bill to legalize and regulate adult-use cannabis sales. If the Aloha State's House committees continue to advance the legislation, Hawaii could join the 24 other states that have both medical and recreational cannabis markets. That invites the question, however—what is the current state of cannabis marketing in Hawaii? We dive into the current advertising regulations that shape medical cannabis brands like Big Island Grown on Hawai'i, O'ahu, Maui, Kaua'i and other islands: https://lnkd.in/gfRP3XEv

The Delhi High Court’s recent decision in Mankind Pharma Limited vs. Sanshiv Health Tech Private Limited highlights the judiciary’s increasing caution and strict approach towards trademark and copyright infringement in the pharmaceutical sector. Justice Saurabh Banerjee’s observation that courts must be stringent when dealing with such cases emphasizes the potential harm to the general public when confusion between similar products arises. This is particularly important in the pharmaceutical industry, where product mix-ups can have serious health consequences. In this case, the court granted an interim injunction in favor of Mankind Pharma to restrain Sanshiv Health from selling its nutritional supplement ‘Calika-P,’ which was found to be deceptively similar to Mankind Pharma’s ‘Caldikind’ and ‘Caldikind-P’ products. The court’s analysis pointed out that the trade dress, label, and trademark of both products were almost indistinguishable, leading to a likelihood of consumer confusion. This confusion, the court observed, could have serious repercussions given the nature of the products involved. The decision underscores the need for vigilance in protecting intellectual property in the healthcare sector, where public interest must be prioritized. By proactively stepping in to restrain Sanshiv Health, the court not only safeguarded Mankind Pharma’s trademark rights but also acted in the interest of preventing consumer deception. The case also serves as a reminder to companies to ensure that their branding and packaging do not ride on the goodwill of established products, as courts are likely to intervene decisively in such matters.

Global cannabis updates: Germany legalizes personal cannabis use, Ohio K-9 law changes, UN calls for medical cannabis equity, Jamaica exports THC, and Ohio billboard ban for dispensaries. Stay informed with the latest cannabis news! 🌿 #CannabisNews #Legalization

EU citizens rally for medical cannabis but face a rigid European Commission 🌿 In the EU, access to medical cannabis is a matter of national policy. A group of citizens wants to change that by leveraging a citizens’ initiative and prompting the European Commission to act. ✍️ Full article by Bregt Raus: https://lnkd.in/euH-ghu2. #ALTIUS #cannabis #cannabislegalization #cannabisnews #lifescienceslaw

Surprising to see only 2 of the big licenses applied for so far, with more applications for smaller licenses. I'm sure that will shift as we get closer to the end of the month. The lack of safety compliance applicants is also definitely concerning. To put some very rough numbers to the mismatch, assuming all cultivation licenses are awarded, and they all build out their full canopy limit (unlikely), KY could have as much as 115,000 square feet of canopy. As defined in KY law, that amount of canopy would be expected to produce more than 55 million grams, or 120k lbs, of wet flower a year. That could be a very big burden for just 2 labs.

There seems to be some confusion on the difference between app stacking with multiple LLCs under the same parent company. Versus multiple businesses getting a provisional lease on the same address. If you have questions feel free to reach out. Bottom line: app stacking is not allowed. Provisional leases are.